Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Pavel J Jedlicka

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Pathology
Phone303/724-8161

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Koubová J, Pangrácová M, Jankásek M, Lukšan O, Jehlík T, Brabcová J, Jedlicka P, Krivánek J, Capková Frydrychová R, Hanus R. Long-lived termite kings and queens activate telomerase in somatic organs. Proc Biol Sci. 2021 Apr 28; 288(1949):20210511. PMID: 33878922.
      View in: PubMed
    2. Tokan V, Rodriguez Lorenzo JL, Jedlicka P, Kejnovska I, Hobza R, Kejnovsky E. Quadruplex-Forming Motif Inserted into 3'UTR of Ty1his3-AI Retrotransposon Inhibits Retrotransposition in Yeast. Biology (Basel). 2021 Apr 20; 10(4). PMID: 33924086.
      View in: PubMed
    3. McCann TS, Parrish JK, Hsieh J, Sechler M, Sobral LM, Self C, Jones KL, Goodspeed A, Costello JC, Jedlicka P. KDM5A and PHF2 positively control expression of pro-metastatic genes repressed by EWS/Fli1, and promote growth and metastatic properties in Ewing sarcoma. Oncotarget. 2020 Oct 27; 11(43):3818-3831. PMID: 33196691.
      View in: PubMed
    4. Sobral LM, Hicks HM, Parrish JK, McCann TS, Hsieh J, Goodspeed A, Costello JC, Black JC, Jedlicka P. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma. Mol Oncol. 2020 10; 14(10):2471-2486. PMID: 32697014.
      View in: PubMed
    5. Sobral LM, Sechler M, Parrish JK, McCann TS, Jones KL, Black JC, Jedlicka P. KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma. Genes Cancer. 2020; 11(1-2):53-65. PMID: 32577157.
      View in: PubMed
    6. McCann TS, Sobral LM, Self C, Hsieh J, Sechler M, Jedlicka P. Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview. Expert Opin Ther Targets. 2019 04; 23(4):267-280. PMID: 30759030.
      View in: PubMed
    7. Parrish JK, McCann TS, Sechler M, Sobral LM, Ren W, Jones KL, Tan AC, Jedlicka P. The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth. Oncotarget. 2018 Sep 04; 9(69):33110-33123. PMID: 30237855.
      View in: PubMed
    8. Jedlicka P. The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers. Expert Opin Ther Targets. 2017 11; 21(11):997-999. PMID: 29022407.
      View in: PubMed
    9. Moore C, Parrish JK, Jedlicka P. MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth. PLoS One. 2017; 12(5):e0178028. PMID: 28542597.
      View in: PubMed
    10. Sechler M, Parrish JK, Birks DK, Jedlicka P. The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis. Oncogene. 2017 07 20; 36(29):4150-4160. PMID: 28319067.
      View in: PubMed
    11. Niemeyer BF, Parrish JK, Spoelstra NS, Joyal T, Richer JK, Jedlicka P. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes. PLoS One. 2015; 10(1):e0116895. PMID: 25603314.
      View in: PubMed
    12. Parrish JK, Sechler M, Winn RA, Jedlicka P. The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma. Oncogene. 2015 Jan 08; 34(2):257-62. PMID: 24362521.
      View in: PubMed
    13. Dylla L, Jedlicka P. Growth-promoting role of the miR-106a~363 cluster in Ewing sarcoma. PLoS One. 2013; 8(4):e63032. PMID: 23638178.
      View in: PubMed
    14. Dylla L, Moore C, Jedlicka P. MicroRNAs in Ewing Sarcoma. Front Oncol. 2013; 3:65. PMID: 23543617.
      View in: PubMed
    15. Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res. 2012 Aug; 10(8):1098-108. PMID: 22723308.
      View in: PubMed
    16. McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK, Jedlicka P. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene. 2011 Dec 08; 30(49):4910-20. PMID: 21643012.
      View in: PubMed
    17. Jedlicka P. Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol. 2010 Mar 19; 3(4):338-47. PMID: 20490326.
      View in: PubMed
    Jedlicka's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)